A Cohort Study in Newly Diagnosed MZL

Status Recruiting

Clinical Trial Summary

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Clinical Trial Description

Marginal zone lymphoma (MZL) originates from the marginal zone of lymphatic follicles and can occur in the spleen, lymph nodes and mucosal lymphoid tissues, and the incidence increases with age. The clinicopathological features of each subtype of MZL are heterogeneous, and their clinical manifestations, biology, etiology, and treatment are all quite heterogeneous, and there is still significant uncertainty about the optimal treatment pathway. This prospective, multicenter, cohort study aims to describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of MZL, and to observe the therapeutic efficacy and safety of different treatment modalities. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06449885
Study type	Observational
Source	Fudan University
Contact	Rong Tao, M.D
Phone	86-21-64175590
Email	rtao@shca.org.cn
Status	Recruiting
Phase
Start date	May 30, 2024
Completion date	June 30, 2034

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03078855` - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma	Phase 3
Recruiting	`NCT06006117` - Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma	Phase 3
Active, not recruiting	`NCT04082936` - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04883437` - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	Phase 2
Active, not recruiting	`NCT03697512` - MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas	Phase 2
Terminated	`NCT00772668` - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL	N/A
Terminated	`NCT04189952` - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma	Phase 2
Terminated	`NCT02877082` - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	Phase 2
Recruiting	`NCT05006716` - A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies	Phase 1/Phase 2
Terminated	`NCT03919175` - Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma	Phase 2
Recruiting	`NCT06026319` - CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma	Phase 1
Active, not recruiting	`NCT03133221` - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Phase 2
Terminated	`NCT01500538` - A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)	Phase 2
Not yet recruiting	`NCT05923502` - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Active, not recruiting	`NCT04646395` - Study of Acalabrutinib and Tafasitamab in MZL Patients	Phase 2
Recruiting	`NCT04116437` - Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment	Phase 2
Completed	`NCT02242045` - Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)	Phase 1
Completed	`NCT02927964` - TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma	Phase 1/Phase 2
Recruiting	`NCT04072458` - A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies	Phase 1
Completed	`NCT03364231` - Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma	Phase 2